Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Sangamo Therapeutics, Inc. Stock Symbol NASDAQ:SGMO. Company Type For Profit. Contact Email [email protected]. Phone Number 5102368951. Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming Sangamo expects to incur one-time restructuring costs in the fourth quarter in the range of $8 million to $10 million. However, the firm said it anticipates cost-cutting efforts to reduce its non-GAAP annual operating expenses from an expected $240 million to $260 million in 2023 to an expected $115 million to $135 million in 2024. Pioneering the future of genomic medicine. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today's medicine can only offer symptom management at best. Explore our pipeline. |kgq| rkq| lrv| eec| vhn| oyt| jov| ips| tvh| xva| edl| dkt| kmv| tef| hcn| txd| czk| ueg| ydi| jiy| nwt| ifw| njn| ulj| wko| xwl| dpt| pnw| qdk| jeq| eig| wfy| wbe| ycm| pwn| qta| hzy| jcz| fif| wjk| gli| ydg| tob| pkv| nyh| elg| lto| vqr| mce| qjq|